Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study.

ABSTRACT:

Background

Circulating tumour DNA (ctDNA) is a promising biomarker to guide clinical decision-making. The aim of this study was to investigate the prognostic value of postoperative ctDNA in patients with stage III colon cancer who received adjuvant chemotherapy (ACT).

Methods

PROVENC3 was a multicentre prospective study of patients who underwent resection of pathological stage III colon cancer. Blood samples were collected at a median of 13 (interquartile range 4-20) days after resection. The presence of minimal residual disease was determined using Labcorp® Plasma Detect™, a novel tumour-informed whole genome sequencing (WGS) ctDNA test. The primary endpoint was 3-year time to recurrence (TTR). ctDNA status was further combined with pathological risk status to investigate t

SUBMITTER: Rubio-Alarcon C 

PROVIDER: S-EPMC12785881 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature